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Pathology of C3 Glomerulopathy
C3 glomerulopathy is a renal disorder involving dysregulation of alternative path-
way complement activation. In most instances, a membranoproliferative pattern 
of glomerular injury with a prevalence of C3 deposition is observed by immuno-
fluorescence microscopy. Dense deposit disease (DDD) and C3 glomerulonephritis 
(C3GN) are subclasses of C3 glomerulopathy that are distinguishable by electron 
microscopy. Highly electron-dense transformation of glomerular basement mem-
brane is characteristic of DDD. C3GN should be differentiated from post-infectious 
glomerulonephritis and other immune complex-mediated glomerulonephritides 
showing C3 deposits.
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Introduction
Glomerulonephritides due to alternative complement pathway dysregula­
tion are presently categorized as C3 glomerulopathy1). However, the scope of 
C3 glomerulopathy is somewhat blurred for the following reasons: (i) Some 
entities, such as atypical hemolytic uremic syndrome (aHUS), may share 
alternative pathway dysregulation yet differ distinctly in clinicopathologic 
features2); (ii) Various glomerulopathies may show predominance or co­
dominance of C3 deposition (relative to other immunoglobulins or comple­
ment types) by immunofluorescence (IF), post­infectious glomerulonephritis 
(PIGN) being a prime example3); and (iii) Laboratory testing for alternative 
pathway dysregulation is not widely available at present, leaving the current 
IF standard of measure as the sole determinant of C3 glomerulopathy4). Al­
though this subject is complex, the historical aspects of C3 glomerulopathy, 
its pathogenesis, and pertinent renal biopsy findings are addressed herein.
Historical aspects of disease classification
C3 glomerulopathy is a relatively new disease class established by interna­
tional consensus in 20135). Prior to this time, little was known of the related 
pathophysiology, so many cases previously diagnosed as membranoprolifera­
tive glomerulonephritis (MPGN) on morphologic grounds would now qua­
lify as C3 glomerulopathy. Membranoproliferative is a descriptive term, refer­
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ring to the most common light microscopic finding in such 
instances and signifying that both glomerular basement 
membrane (GBM) and related cellular components (me­
sangial, endothelial, and endocapillary) are duly altered6).
Repeated past efforts to subclassify MPGN have gradu­
ally advanced the understanding and optimal treatment 
strategies for each subgroup. Despite the impression of 
homogeneity by light microscopy (LM), three subgroups 
of MPGN (I–III) emerged, defined by electron microscopy 
(EM). Subendothelial deposits were characteristic of MPGN 
type I7); and dense deposit disease (DDD), named for its 
unique electron­dense transformation of GBM, corres­
ponded with MPGN type II8). MPGN type III included two 
distinct forms: the Burkholder variant, showing additional 
subepithelial immune deposits9); and the Strife and Anders 
variant, demonstrating thickened glomerular capillary 
walls and destruction of GBM by intramembranous de­
posits10,11). MPGN type II (or DDD) was deemed the most 
distinctive of these subgroups, given its hallmark EM 
findings. However, studies conducted during the 2000’s 
revealed that membranoproliferative patterns by LM were 
confined to a minority (25–44%) of patients with DDD12,13), 
suggesting substantial differences in the pathophysiology 
of DDD versus other types of MPGN.
In addition to LM and EM features, IF studies have pro­
vided critical etiologic clues in this setting fueling the C3 
glomerulopathy disease concept. Early investigations from 
the 1970’s had delineated two distinct IF patterns in ins­
tances of MPGN7,14,15), one of which glomerular deposits of 
immunoglobulin and C3 both occur and the other is li­
mited to isolated C3 deposition. The former was explained 
by triggering of complement activation via classical (im­
mune complex­based) or lectin (foreign substance­induced) 
pathways, whereas isolated C3 deposition was attributed 
to alternative pathway complement activation.
Fakhouri et al. subsequently introduced C3 glomerulo­
pathy as a new disease class imposed by isolated C3 glo­
merular deposition (in the absence of immunoglobulin), 
with or without visible membranoproliferative features16). 
They also defined two subsets of C3 glomerulopathy: DDD 
bearing dense osmiophilic deposits of mesangium, GBM, 
and tubular basement membrane and C3 glomerulo­
nephritis (C3GN), a relatively rare and heterogeneous 
variant with less discrete EM deposits. Although morpho­
logically disparate, DDD and C3GN are similar in etiology 
and fall within the same disease spectrum16).
Countless efforts to reach an international consensus on 
the C3 glomerulopathy paradigm finally bore fruit during 
the first C3 Glomerulopathy Meeting held in August, 2012 
5). This gathering of experts in nephrology, renal pathology, 
complement biology, and complement therapeutics sought 
to provide a formal definition of the disease and establish 
guidelines for future research5). Unlike the criteria first 
proposed, they described C3 glomerulopathy as “a disease 
process due to abnormal control of complement activation, 
deposition, or degradation and characterized by predomi­
nant glomerular C3 fragment deposition with electron­
dense deposits in EM”. This description implies that small 
amount of immunoglobulin deposits can be observed in 
C3 glomerulopathy and that diagnosis of C3 glomerulo­
pathy must rely on IF, LM, EM, and clinical features5).
Pathophysiology of C3 glomerulopathy
As an important innate defense mechanism against 
pathogenic stimuli, the complement system includes >30 
components and regulators17). There are three complement 
activation pathways: classical, lectin, and alternative. The 
classical pathway, incorporating C1q, C1r, C1s, C4, and C2 
components, is activated by antigen­antibody immune 
complexes. The lectin pathway, in which C2 and C4 also 
have roles, is activated by attachment of mannose­binding 
lectin to microbial carbohydrate groups17,18). The alternative 
pathway is unique in its continual activation by sponta­
neous C3 hydrolysis, forming C3 convertase (so­called 
“tick­over” process)19). Generation of C3 convertase and its 
downstream products is tightly regulated by various com­
ponents of the complement system, so any inherent defects 
or autoantibody assaults may eventuate in alternative path­
way dysregulation17,20). The mechanism of alternative path­
way dysregulation in the context of C3 glomerulopathy is 
highly complex, as is regulating the complement system 
itself. Factors contributing to this dysfunction may be 
categorized by mechanism of action.
1. Autoantibodies to alternative pathway regulators
C3 nephritic factors (C3NeFs) are IgG or IgM autoanti­
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bodies targeting neoepitopes of alternative pathway C3 
convertase (C3bBb)21,22). C3bBb converts C3 to C3b in con­
junction with complement factor B (FB) and complement 
factor D; and in an amplification loop, factor Bb attached 
to C3b converts more C3 to C3b23). C3 convertase is de­
graded very quickly by negative regulators, such as decay­
accelerating factor (CD55), complement factor H (FH), 
and complement receptor 1, thus preventing uncontrolled 
tissue injury. C3NeFs prolong the half­life of C3bBb 
through interference with these regulators24­26). They are 
also found in many patients with DDD (70–80%) or C3GN 
(40–55%)26). C5 nephritic factors (C5NeFs) are autoanti­
bodies that stabilize C5 convertase (C3bBbC3b) of the al­
ternative pathway, thereby affecting serum C5b­9 levels. 
Marinozzi et al. have demonstrated C3NeFs in more than 
half of patients with C3GN, although C3NeFs and C5NeFs 
in combination or C5NeFs alone may be present; and 
C5NeFs are more frequently associated with C3GN than 
with DDD27). C4 nephritic factors (C4NeFs) stabilize the 
C3 convertase (C4bC2a) of classical and lectin pathways. 
There is evidence of sporadic C4NeF positivity in patients 
with C3GN, although the recorded prevalence varies28,29). 
The functions of these nephritic factors often require the 
presence of properdin17,26,27). In addition to previous the­
rapeutic trials like plasmapheresis, anti­cellular immune 
therapy and eculizumab5), properdin is currently under 
scrutiny for its therapeutic utility30). In addition to nephritic 
factors, autoantibodies aimed at other regulators or com­
ponents of the complement pathway (i.e., FH and FB) have 
been detected31,32).
2. Genetic alterations
Apart from acquired causes of C3 glomerulopathy thus 
far discussed, aberrant complement­related genes are 
similarly implicated, including variants of CFH (affecting 
FH), CFI (affecting factor I), CFB, and C3 (affecting C3 
convertase and C5 convertase)1,20). Factor H­related (FHR) 
proteins are other modulators of the complement pathway, 
some members (FHR1, FHR2, FHR3, and FHR5) forming 
dimeric complexes under normal conditions. Abnormal 
FHR fusion proteins due to genetic alterations may result 
in C3GN or DDD1,33). The above genetic defects cited for 
C3GN largely overlap with those of aHUS. However, aHUS 
is marked by solid­phase endothelial cell activation of the 
alternative complement pathway, unlike the largely fluid­
phase alternative pathway activation of C3GN18,34,35). Alter­
native pathway dysregulation may also stem from mono­
clonal immunoglobulin production in patients with 
monoclonal gammopathy of renal significance, multiple 
myeloma, and other lymphoproliferative disorders36,37). 
Under such circumstances, monoclonal proteins act as 
autoantibodies targeting FH or FB and then culminate in 
C3 glomerulopathy (monoclonal immunoglobulin­asso­
ciated C3 glomerulopathy)38).
Pathologic features of C3 glomerulopathy 
C3 glomerulopathy is typified by C3 accumulation de­
posited within glomerular mesangium and capillary walls. 
Little or no immunoglobulin is present. IF studies confirm 
an active glomerulonephritis, showing mostly granular or 
semi­linear C3 deposits more intensely stained (2­level at 
least) than other complement or immunoglo bulin proteins. 
IgG, IgM, IgA, and C1q deposits may well be present, but 
not at levels comparable to C3 (Fig. 1A, B), and C4d depo­
sition is rarely seen5,39).
Electron­dense glomerular deposits are identified in all 
forms of C3 glomerulopathy and serve to differentiate the 
two major subtypes of C3 glomerulopathy: DDD and 
C3GN5). DDD is defined by highly electron­dense and 
osmiophilic intramembranous deposits and resultant 
GBM lamina densa transformation. The deposits appear 
ribbon­ or sausage­like and may even inhabit tubular base­
ment membrane or Bowman’s capsule. In patients with 
C3GN, these deposits are ill­defined and not as highly elec­
tron­dense, involving mesangium and subendothelial re­
gions (Fig. 1C, D). Rarely are they subepithelial or intra­
membranous in nature. They resemble those commonly 
seen in immune complex­mediated glomerulonephritis. 
So­called “hump­like” subepithelial deposits, similar to 
those manifested in PIGN, may be identified at times. 
LM findings of C3 glomerulopathy are diverse, ranging 
from near­normal morphology to features of proliferative 
(mesangial, membranous, or endocapillary), crescentic, or 
sclerosing glomerulonephritis. The pattern witnessed in 
C3GN is usually that of MPGN (Fig. 1E, F)40­43), characte­
rized by mesangial expansion with hypercellularity and 
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thickened (i.e., doubly contoured) glomerular capillary 
walls. In one series, MPGN patterns accounted for 71% of 
patients with C3GN42). The others primarily showed me­
sangial proliferation, without changes in glomerular capil­
laries. Some will lack mesangial proliferation altogether, 
mimicking minimal change disease. The glomeruli may 
show endocapillary proliferation, with variable inflamma­
tory cell infiltrates, and crescents may be encountered5,42,44).
In a large series of patients with DDD, the most common 
histologic pattern was mesangial proliferative GN (43.4%), 
followed by membranoproliferative (24.6%), crescentic 
(17.4%), and endocapillary proliferative (11.6%) glomerulo­
nephritis13). Other cohorts have most often displayed fea­
tures of MPGN (43.8–77.8%), followed by mesangial pro­
liferative glomerulonephritis12,45,46). 
Differential diagnosis of C3 glomerulopathy 
1. C3 glomerulonephritis versus dense deposit disease
DDD is sometimes difficult to distinguish from C3GN5, 
47). As noted earlier, C3 glomerulopathy in the absence of 
highly electron­dense, ribbon­like deposits by EM is classi­
fiable as C3GN; and the electron­dense deposits of C3GN 
are more often found in mesangial and subendothelial 
regions, seldom occupying the intramembranous and sub­
epithelial areas typical of DDD48). Assessments of deposit 
density are subjective, frequently sparking disagreement 
among pathologists in their classification of DDD vs C3GN 
5,47,49­52). Furthermore, the ribbon­like deposits of DDD are 
generally discontinuous, creating the potential for sampling 
error and subsequent misdiagnosis as C3GN. There are no 
other specific LM criteria for differentiating between DDD 
and C3GN, except when intramembranous deposits stain 
intensely by Periodic acid­Schiff8,53). Such deposits are 
fuchsinophilic in trichrome stains and lack methenamine 
silver positivity53).
The ratio of DDD to C3GN is reportedly about 1:342,54). It 
may be necessary to distinguish between DDD and C3GN 
for prognostic or therapeutic studies that compare respec­
tive outcomes. There is greater likelihood of C3NeFs42) and 
lower circulating C3 levels in patients with DDD (vs C3GN) 
54). Otherwise, no clear clinical differences are evident. 
2. Immune complex-mediated glomerulonephritis 
By definition, glomerular C3 deposition in patients with 
C3 glomerulopathy is at least 2­level more intensely stained 
in IF preparations than are other complement or immuno­
globulin deposits. However, the distinction between C3 
glomerulopathy and MPGN is not always obvious on this 
basis. In terms of the latter, glomerular staining of C4d (a 
byproduct of activated classical and lectin pathways) may 
be helpful55). C4d staining is negative or trace in instances 
of C3 glomerulopathy, whereas immune complex­mediated 
glomerulonephritis yields positive results55­57).
3. Post-infectious glomerulonephritis
PIGN is a self­limited glomerulonephritis commonly 
triggered by streptococcal infection58) and reflecting a bac­
terial immunologic response. The findings are those of im­
mune complex­mediated disease. Diffuse endocapillary 
Fig. 1. Typical morphologic features of C3 glomerulopathy: 
Immu nofluorescence preparations show (A) strong granular 
staining of glomerular C3 deposits (within mesangium and 
along capil lary walls) as well as (B) trace IgG. Electron micro-
scopic examina tion confirms multiple electron-dense deposits 
of (C) mesangium (×6,000) and (D) subendothelial regions 
(×7,000). Light micro scopy displays (E) mesangial prolifer ation 
(Periodic acid-Schiff, ×400) and (F) double-contoured capillary 
walls (methe namine silver, ×400), indicating membranoprolife-
rative glomerulonephritis. 
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glomerulonephritis, deposition of IgG and C3, and suben­
dothelial and subepithelial hump­like deposits are usually 
visible by LM, IF, and EM, respectively. 
Difficulty may arise in distinguishing some cases of PIGN 
from C3GN. C3 amplification may outlast immunoglo­
bulin, and C3­predominant or isolated C3 deposits may 
exist59). C3GN may then sporadically present as a diffuse 
endocapillary proliferative pattern5,48,54,60), and hump­like 
subepithelial deposits are frequent accompaniments of 
both MPGN and C3GN48). The clinical course and labora­
tory findings are perhaps helpful in this regard. Patients 
with PIGN readily recover baseline kidney function and 
laboratory profiles in a matter of weeks, resolving hema­
turia, proteinuria, and hypocomplementemia without 
therapeutic intervention. Prolonged proteinuria and low 
serum C3 levels are clinically indicative of chronic glome­
rulonephritis. However, initial PIGN presentations have 
seemingly morphed into C3 glomerulopathy57,61,62), trans­
formed (it now appears) by complement activation via 
alternative pathway61­64). Various sources have also noted 
the presence of nephritis­associated plasmin receptor 
(NAPlr) in instances of PIGN with C3 glomerulopathy 
features63,65,66). As shown by Sethi et al., most cases of PIGN 
plagued by persistent hematuria and proteinuria have in­
volved underlying defects, either genetic mutations, auto­
antibodies, or both, that impact alternative complement 
pathway regulation57). Before conceding a diagnosis of C3 
glomerulopathy in patients with C3­predominant PIGN, 
persistent hypocomplementemia, and proteinuria or de­
clining renal function, further investigation of the alterna­
tive complement pathway is consequently advised3,5).
Conclusion
C3 glomerulopathy is a recently established disease 
entity pathogenetically linked to alternative complement 
pathway dysregulation. The histologic patterns entailed 
are diverse, membranoproliferative being the most com­
mon. Based on distinctive EM features, DDD and C3GN 
are specific subtypes of C3 glomerulopathy, both requiring 
differentiation from other glomerulopathies marked by a 
predominance of C3 deposition.
Conflict of interest
The authors declare that they have no conflicts of interest.
ORCID




1. Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, 
e t al. C3 glomerulopathy - understanding a rare complement-
driven renal disease. Nat Rev Nephrol 2019;15:129-43.
2. Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017; 
31:213-23.
3. Khalighi MA, Wang S, Henriksen KJ, Bock M, Keswani M, Meehan 
SM, et al. Revisiting post-infectious glomerulonephritis in the 
emerging era of C3 glomerulopathy. Clin Kidney J 2016;9:397-
402.
4. Ito N, Ohashi R, Nagata M. C3 glomerulopathy and current dil-
emmas. Clin Exp Nephrol 2017;21:541-51.
5. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel 
GB, et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 
84:1079-89.
6. Alchi B, Jayne D. Membranoproliferative glomerulonephritis. 
Pediatr Nephrol 2010;25:1409-18.
7. Levy M, Gubler MC, Sich M, Beziau A, Habib R. Immunopathology 
of membranoproliferative glomerulonephritis with subendo-
thelial deposits (Type I MPGN). Clin Immunol Immunopathol 
1978;10:477-92.
8. Habib R, Gubler MC, Loirat C, Maiz HB, Levy M. Dense deposit 
disease: a variant of membranoproliferative glomerulonephritis. 
Kidney Int 1975;7:204-15.
9. Burkholder PM, Marchand A, Krueger RP. Mixed membranous 
and proliferative glomerulonephritis. A correlative light, immu-
nofluorescence, and electron microscopic study. Lab Invest 
1970;23:459-79.
10  Strife CF, McEnery PT, McAdams AJ, West CD. Membranopro-
liferative glomerulonephritis with disruption of the glomerular 
basement membrane. Clin Nephrol 1977;7:65-72.
11. Anders D, Agricola B, Sippel M, Thoenes W. Basement membrane 
changes in membranoproliferative glomerulonephritis. II. Cha-
racterization of a third type by silver impregnation of ultra thin 
sections. Virchows Arch A Pathol Anat Histol 1977;376:1-19.
12. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, 
et al. Dense deposit disease: clinicopathologic study of 32 pe-
98 Child Kidney Dis • 2019;23:93-99 www.chikd.org
diatric and adult patients. Clin J Am Soc Nephrol 2009;4:22-32.
13. Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is 
not a membranoproliferative glomerulonephritis. Mod Pathol 
2007;20:605-16.
14. Belgiojoso GB, Tarantino A, Bazzi C, Colasanti G, Guerra L, Durante 
A. Immunofluorescence patterns in chronic membranoprolifera-
tive glomerulonephritis (MPGN). Clin Nephrol 1976;6:303-10.
15. Pickering RJ, Herdman RC, Michael AF, Vernier RL, Gewurz H, Fish 
AJ, et al. Chronic glomerulonephritis associated with low serum 
complement activity (chronic hypocomplementemic glomeru-
lonephritis). Medicine (Baltimore) 1970;49:207-26.
16. Fakhouri F, Fremeaux-Bacchi V, Noel LH, Cook HT, Pickering MC. 
C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 
6:494-9.
17. Noris M, Remuzzi G. Overview of complement activation and 
regulation. Semin Nephrol 2013;33:479-92.
18. Bomback AS, Markowitz GS, Appel GB. Complement-Mediated 
Glomerular Diseases: A Tale of 3 Pathways. Kidney Int Rep 2016;1: 
148-55.
19. Nilsson B, Nilsson Ekdahl K. The tick-over theory revisited: Is C3 a 
contact-activated protein? Immunobiology 2012;217:1106-10.
20. Wong EKS, Kavanagh D. Diseases of complement dysregulation-
an overview. Semin Immunopathol 2018;40:49-64.
21. Spitzer RE, Stitzel AE, Tsokos GC. Production of IgG and IgM auto-
antibody to the alternative pathway C3 convertase in normal 
individuals and patients with membranoproliferative glomeru-
lonephritis. Clin Immunol Immunopathol 1990;57:10-8.
22. Jozsi M, Reuter S, Nozal P, Lopez-Trascasa M, Sanchez-Corral P, 
Prohaszka Z, et al. Autoantibodies to complement components 
in C3 glomerulopathy and atypical hemolytic uremic syndrome. 
Immunol Lett 2014;160:163-71.
23. Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L, Giclas PC, 
Goodship TH, de Cordoba SR, et al. Sensitive and specific assays 
for C3 nephritic factors clarify mechanisms underlying com-
plement dysregulation. Kidney Int 2012;82:1084-92.
24. Ito S, Tamura N, Fujita T. Effect of decay-accelerating factor on 
the assembly of the classical and alternative pathway C3 conver-
tases in the presence of C4 or C3 nephritic factor. Immunology 
1989;68:449-52.
25. Zhang Y, Nester CM, Holanda DG, Marsh HC, Hammond RA, 
Thomas LJ, et al. Soluble CR1 therapy improves complement re-
gulation in C3 glomerulopathy. J Am Soc Nephrol 2013;24:1820-
9.
26. Corvillo F, Okroj M, Nozal P, Melgosa M, Sanchez-Corral P, Lopez-
Trascasa M. Nephritic Factors: An Overview of Classification, 
Diagnostic Tools and Clinical Associations. Front Immunol 2019; 
10:886.
27. Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, 
Legendre C, et al. C5 nephritic factors drive the biological pheno-
type of C3 glomerulopathies. Kidney Int 2017;92:1232-41.
28. Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes 
G, et al. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. 
Am J Kidney Dis 2017;70:834-43.
29. Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 
Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clin 
Proc 2018;93:991-1008.
30. Michels M, van de Kar N, van den Bos RM, van der Velden T, van 
Kraaij SAW, Sarlea SA, et al. Novel Assays to Distinguish Between 
Properdin-Dependent and Properdin-Independent C3 Ne-
phritic Factors Provide Insight Into Properdin-Inhibiting Therapy. 
Front Immunol 2019;10:1350.
31. Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin 
B, Buchler M, et al. Anti-factor H autoantibodies in C3 glomeru-
lopathies and in atypical hemolytic uremic syndrome: one 
target, two diseases. J Immunol 2015;194:5129-38.
32. Marinozzi MC, Roumenina LT, Chauvet S, Hertig A, Bertrand D, 
Olagne J, et al. Anti-Factor B and Anti-C3b Autoantibodies in C3 
Glomerulopathy and Ig-Associated Membranoproliferative GN. 
J Am Soc Nephrol 2017;28:1603-13.
33. Goicoechea de Jorge E, Caesar JJ, Malik TH, Patel M, Colledge M, 
Johnson S, et al. Dimerization of complement factor H-related 
proteins modulates complement activation in vivo. Proc Natl 
Acad Sci U S A 2013;110:4685-90.
34. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, Vazquez-
Martul E, Torreira E, Montes T, et al. Human C3 mutation reveals 
a mechanism of dense deposit disease pathogenesis and pro-
vides insights into complement activation and regulation. J Clin 
Invest 2010;120:3702-12.
35. Pickering M, Cook HT. Complement and glomerular disease: new 
insights. Curr Opin Nephrol Hypertens 2011;20:271-7.
36. Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy 
associated with monoclonal Ig is a distinct subtype. Kidney Int. 
2018;94:178-86.
37. Sethi S, Rajkumar SV, D'Agati VD. The Complexity and Hetero-
geneity of Monoclonal Immunoglobulin-Associated Renal 
Diseases. J Am Soc Nephrol. 2018;29:1810-23.
38. Sethi S, Fervenza FC, Rajkumar SV. Spectrum of manifestations 
of monoclonal gammopathy-associated renal lesions. Curr Opin 
Nephrol Hypertens 2016;25:127-37.
39. Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry 
Stokes M, et al. Toward a working definition of C3 glomerulo-
pathy by immunofluorescence. Kidney Int 2014;85:450-6.
40. Yagi K, Yanagida H, Sugimoto K, Kuwajima H, Tabata N, Morita K, 
et al. Clinicopathologic features, outcome, and therapeutic in-
terventions in four children with isolated C3 mesangial prolife-
rative glomerulonephritis. Pediatr Nephrol 2005;20:1273-8.
41. Cook HT. C3 glomerulopathy. F1000Res 2017;6:248.
42. Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon- 
Durey MA, et al. Acquired and genetic complement abnorma-
lities play a critical role in dense deposit disease and other C3 
glomerulopathies. Kidney Int 2012;82:454-64.
43. Viswanathan GK, Nada R, Kumar A, Ramachandran R, Rayat CS, 
Jha V, et al. Clinico-pathologic spectrum of C3 glomerulopathy-
Shin SJ, et al. • C3 Glomerulopathy 99www.chikd.org
an Indian experience. Diagn Pathol 2015;10:6.
44  Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulone-
phritis with a severe crescentic phenotype. Pediatr Nephrol 
2017;32:1625-33.
45. Prema KSJ, Kurien AA, Gopalakrishnan N, Walker PD, Larsen CP. 
Dense deposit disease: a greatly increased biopsy incidence in 
India versus the USA. Clin Kidney J 2019;12:476-82.
46. Park SJ, Kim YJ, Ha TS, Lim BJ, Jeong HJ, Park YH, et al. Dense de-
posit disease in Korean children: a multicenter clinicopathologic 
study. J Korean Med Sci 2012;27:1215-21.
47. Sethi S, Fervenza FC, Smith RJ, Haas M. Overlap of ultrastructural 
findings in C3 glomerulonephritis and dense deposit disease. 
Kidney Int 2015;88:1449-50.
48. Cook HT, Pickering MC. Histopathology of MPGN and C3 glo-
merulopathies. Nat Rev Nephrol 2015;11:14-22.
49. Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, et al. 
Proliferative glomerulonephritis secondary to dysfunction of 
the alternative pathway of complement. Clin J Am Soc Nephrol 
2011;6:1009-17.
50. Bridoux F, Desport E, Fremeaux-Bacchi V, Chong CF, Gombert JM, 
Lacombe C, et al. Glomerulonephritis with isolated C3 deposits 
and monoclonal gammopathy: a fortuitous association? Clin J 
Am Soc Nephrol 2011;6:2165-74.
51 Hawf ield A, Iskandar SS, Smith RJ. Alternative pathway dysfunc-
tion in kidney disease: a case report and review of dense deposit 
disease and C3 glomerulopathy. Am J Kidney Dis 2013;61:828-31.
52. Strife CF, West CD, Witte DP. Crescentic glomerulonephritis in 
childhood: acute nonproliferative glomerulitis versus dense 
deposit disease. Am J Kidney Dis 2003;41:897; author reply 8.
53. Churg J, Duffy JL, Bernstein J. Identification of dense deposit 
disease: a report for the International Study of Kidney Diseases in 
Children. Arch Pathol Lab Med 1979;103:67-72.
54. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor 
C, Flanagan M, Wong L, et al. C3 glomerulopathy: clinicopatho-
logic features and predictors of outcome. Clin J Am Soc Nephrol 
2014;9:46-53.
55. Sethi S, Nasr SH, De Vriese AS, Fervenza FC. C4d as a Diagnostic 
Tool in Proliferative GN. J Am Soc Nephrol. 2015;26:2852-9.
56. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi 
V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and 
C3 glomerulopathy: conclusions from a "Kidney Disease: Im-
proving Global Outcomes" (KDIGO) Controversies Conference. 
Kidney Int 2017;91:539-51.
57. Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, et al. 
Atypical postinfectious glomerulonephritis is associated with 
abnormalities in the alternative pathway of complement. Kidney 
Int 2013;83:293-9.
58. Kanjanabuch T, Kittikowit W, Eiam-Ong S. An update on acute 
postinfectious glomerulonephritis worldwide. Nat Rev Nephrol 
2009;5:259-69.
59. Fish AJ, Herdman RC, Michael AF, Pickering RJ, Good RA. Epide-
mic acute glomerulonephritis associated with type 49 strepto-
coccal pyoderma. II. Correlative study of light, immunofluorescent 
and electron microscopic findings. Am J Med 1970;48:28-39.
60. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 
glomerulonephritis: clinicopathological findings, complement 
abnormalities, glomerular proteomic profile, treatment, and 
follow-up. Kidney Int 2012;82:465-73.
61. Sandhu G, Bansal A, Ranade A, Jones J, Cortell S, Markowitz GS. 
C3 glomerulopathy masquerading as acute postinfectious glo-
merulonephritis. Am J Kidney Dis 2012;60:1039-43.
62. Vernon KA, Goicoechea de Jorge E, Hall AE, Fremeaux-Bacchi V, 
Aitman TJ, Cook HT, et al. Acute presentation and persistent glo-
merulonephritis following streptococcal infection in a patient 
with heterozygous complement factor H-related protein 5 de-
ficiency. Am J Kidney Dis 2012;60:121-5.
63. Suga K, Kondo S, Matsuura S, Kinoshita Y, Kitano E, Hatanaka M, 
et al. A case of dense deposit disease associated with a group A 
streptococcal infection without the involvement of C3NeF or 
complement factor H deficiency. Pediatr Nephrol 2010;25:1547-
50.
64. Prasto J, Kaplan BS, Russo P, Chan E, Smith RJ, Meyers KE. Strepto-
coccal infection as possible trigger for dense deposit disease (C3 
glomerulopathy). Eur J Pediatr 2014;173:767-72.
65. Sawanobori E, Umino A, Kanai H, Matsushita K, Iwasa S, Kitamura 
H, et al. A prolonged course of Group A streptococcus-associated 
nephritis: a mild case of dense deposit disease (DDD)? Clin Ne-
phrol 2009;71:703-7.
66. Okabe M, Tsuboi N, Yokoo T, Miyazaki Y, Utsunomiya Y, Hosoya T. 
A case of idiopathic membranoproliferative glomerulonephritis 
with a transient glomerular deposition of nephritis-associated 
plasmin receptor antigen. Clin Exp Nephrol 2012;16:337-41.
